Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung cancer: final, 6-year outcomes from CheckMate 9LA

Carbone, D.P.; Ciuleanu, T.-E.; Cobo, M.; Schenker, M.; Zurawski, B.; Menezes, J.; Richardet, E.; Felip, E.; Cheng, Y.; Juan-Vidal, O.; Alexandru, A.; Mizutani, H.; Reinmuth, N.; Lu, S.; Reck, M.; John, T.; Scherpereel, A.; De Marchi, P.; Aoyama, T.; Sathyanarayana, P.; Grootendorst, D.J.; Hu, N.; Ip, V.; Hung, Y.-H.; Paz-Ares, L.G.

doi:10.1016/j.esmoop.2025.105123

Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung cancer: final, 6-year outcomes from CheckMate 9LA

Background The phase III CheckMate 9LA study demonstrated durable overall survival (OS) benefit with nivolumab plus ipilimumab with chemotherapy versus chemotherapy in patients with metastatic non-small-cell lung cancer (NSCLC). Here, we report final, 6-year efficacy and safety outcomes. Patients…